TY - JOUR
T1 - Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia
AU - Fava, Carmen
AU - Cortes, Jorge
N1 - Funding Information:
STATEMENT OF CONFLICT OF INTEREST: Dr Cortes has received research grant support from Novartis Pharmaceuticals Corp; Dr. Fava has no relationships with the supplement sponsor to disclose.
PY - 2009/1
Y1 - 2009/1
N2 - Imatinib is now established as the gold standard first-line therapy for patients with chronic myeloid leukemia (CML). Responses to imatinib are superior to those seen with interferon alfa and also occur earlier, demonstrating a stronger and deeper response to therapy. Imatinib therapy also provides long-term clinical benefit and outcomes, with improved progression-free survival (PFS) and overall survival (OS) compared with historical controls, at 6 years of follow-up. Recent data show that annual event rates decline over time with imatinib therapy, suggesting that long-term disease control is possible in continuously responding patients. Despite these treatment successes, new strategies are continually being evaluated to maximize responses to imatinib and ensure the best treatment outcomes for all patients. For example, high-dose imatinib therapy, with doses up to 800 mg/d, has been shown to improve response rates. Prospective, randomized trials are ongoing to assess the benefits of high-dose imatinib therapy and determine whether it extends PFS and OS compared with standard-dose imatinib.
AB - Imatinib is now established as the gold standard first-line therapy for patients with chronic myeloid leukemia (CML). Responses to imatinib are superior to those seen with interferon alfa and also occur earlier, demonstrating a stronger and deeper response to therapy. Imatinib therapy also provides long-term clinical benefit and outcomes, with improved progression-free survival (PFS) and overall survival (OS) compared with historical controls, at 6 years of follow-up. Recent data show that annual event rates decline over time with imatinib therapy, suggesting that long-term disease control is possible in continuously responding patients. Despite these treatment successes, new strategies are continually being evaluated to maximize responses to imatinib and ensure the best treatment outcomes for all patients. For example, high-dose imatinib therapy, with doses up to 800 mg/d, has been shown to improve response rates. Prospective, randomized trials are ongoing to assess the benefits of high-dose imatinib therapy and determine whether it extends PFS and OS compared with standard-dose imatinib.
UR - http://www.scopus.com/inward/record.url?scp=63249120084&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=63249120084&partnerID=8YFLogxK
U2 - 10.1053/j.seminhematol.2009.01.007
DO - 10.1053/j.seminhematol.2009.01.007
M3 - Article
C2 - 19621543
AN - SCOPUS:63249120084
SN - 0037-1963
VL - 46
SP - S5-S10
JO - Seminars in Hematology
JF - Seminars in Hematology
IS - SUPPL. 3
ER -